UCB - Operating Expenses



UCB reported EUR2.36B in Operating Expenses for its fiscal semester ending in December of 2024.


Operating Expenses Change Date
Alcon AG USD 2.35B 344M Jun/2025
Almirall EUR 517.43M 265.53M Jun/2025
Amarin USD 58.77M 56.06M Mar/2025
argenx SE USD 744.12M 92.38M Jun/2025
AstraZeneca USD 10.95B 1.04B Jun/2025
Bayer EUR 10.73B 688M Jun/2025
Galapagos EUR 122.32M 111.37M Jun/2025
Genmab DKK 565M 38M Jun/2025
GlaxoSmithKline GBP 5.96B 663M Jun/2025
GRIFOLS EUR 1.54B 24.64M Jun/2025
Hikma Pharmaceutical USD 1.31B 63M Dec/2024
Lonza CHF 3.09B 564M Dec/2024
Merck EUR 4.22B 49M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Orion EUR 311.9M 35.2M Jun/2025
Recordati EUR 493.93M 9.74M Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024
Sanofi EUR 9.02B 702M Jun/2025
UCB EUR 2.36B 108M Dec/2024
Unibail Rodamco EUR 1.18B 844M Dec/2024